December 2022

Bristol Trials Centre: Achievements in 2022

2022 has been a great year for the Bristol Trials Centre.

  • 17 studies are currently open to recruitment
  • 6 studies are in follow up
  • 20 studies have completed follow up
  • Over 3,500 participants have been recruited
  • ~14 journal articles have been accepted for publication

Thank you to all staff members for their hard work and dedication to managing and delivering high quality research.




As the OMACS study closes recruitment, over 4000 cardiac surgery patients have donated data and samples to be banked for future research.

The OMACS study closed recruitment at the end of May 2022, nearly 6 years after opening. The study objective was to create a bank of data and biological samples from patients undergoing cardiac surgery at the Bristol Heart Institute (BHI). The data and samples will be stored long term and are available for secondary researchers to analyse.

The OMACS study team aimed to approach all patients undergoing cardiac surgery at the BHI for consent. A total of 4069 patients consented to donate their clinical data with 1236 also donating pre- and post-operative biological samples.

This bank of data and samples allows a multitude of research questions to be answered which could improve patient care in the future. To date researchers have used the OMACS samples and/or data to investigate the following topics:

  1. Predictors of post-operative acute kidney injury.
  2. Predictors of post-operative atrial fibrillation.
  3. Predictors of coagulopathic bleeding.
  4. Identifying stem cells in human arteries and investigating whether they could be used for therapeutic applications.
  5. The impact of the COVID-19 pandemic on clinical study recruitment, retention and patient outcomes.
  6. Inflammatory response and cerebral injury in patients undergoing traditional or minimally invasive cardiac surgery

The data and samples remain available for ethically approved secondary research.

For more information, contact the team:


This work was supported by the UK National Institute for Health Research Bristol Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the UK NIHR, Department of Health and Social Care, or NHMRC. The OMACS study was designed and delivered in collaboration with the Bristol Trials Centre, a UKCRC registered clinical trials unit (CTU), which is in receipt of NIHR CTU support funding.